EQS-News: MEDICLIN presents preliminary figures for the 2024 financial year
|
EQS-News: MEDICLIN AG
/ Key word(s): Preliminary Results
Offenburg, February 27, 2024
MEDICLIN presents preliminary figures for the 2024 financial year
MEDICLIN generated group sales of EUR 748.8 mill. in the 2024 financial year (previous year: EUR 730.1 mill.). The group operating result reached EUR 53.5 mill. and was thus EUR 40.8 mill. higher than in the previous year (previous year: 2023: EUR 12.7 mill.). In 2023, the group operating result was heavily impacted by impairment of goodwill in the acute segment at EUR 33.1 mill. Sales growth and the group operating result are at the upper end of the annual forecast renewed in January 2025 (1.0% to 3.0% and EUR 48.0 to 54.0 mill.).
For more information:Tino Fritz, CFO of MEDICLIN, comments: "The sales growth and the positive development of the group operating result underline our operating performance in the second half of 2024. The consolidated EBIT of EUR 53.5 mill. is the result of the great commitment of the entire MEDICLIN workforce. Development in the segments In the post-acute segment, sales increased by 7.6% to EUR 485.4 mill. (previous year: EUR 451.2 mill.). An operating result of EUR 52.3 mill. was achieved (previous year: EUR 52.7 mill.), which corresponds to a decrease of EUR 0.4 mill. or 0.8%. The sales and earnings performance of the post-acute segment was also positively influenced by a contribution from the “Reha-Klinik am Sendesaal”, which was acquired in 2024. In the acute segment, sales totalling EUR 234.9 mill. were achieved (previous year: EUR 254.0 mill.). The decline in sales is mainly due to the sale of the former „MEDICLIN Herzzentrum Coswig“. The segment operating result amounted to EUR –0.6 mill. in 2024 after EUR –39.9 mill. in 2023. In 2023, it was heavily burdened by goodwill amortisation of EUR 33.1 mill. As part of a reorganisation of segment reporting, we have split the previous "Other Activities" segment into the two independent "Service" and "Nursing care" segments. This reorganisation enables us to respond more specifically to the specific requirements and growth opportunities in these areas. Sales in the nursing care segment rose to EUR 23.4 mill. in the reporting year (previous year: EUR 21.3 mill.), while the operating result in the nursing care segment totalled EUR 0.2 mill., as in the previous year. In the Service segment, sales increased by EUR 13.3 mill. to EUR 94.6 mill.. At EUR 1.7 mill., the segment operating result was up EUR 2.0 mill. on the previous year (previous year: EUR –0.3 mill.). Employees and investments The number of employees (calculated in full-time equivalents) averaged 6,889 in the 2024 reporting year (previous year: 7,016 full-time equivalents). MEDICLIN invested in the future of the Group in 2024 with gross investments totalling EUR 46.2 mill. (previous year: EUR 38.8 mill.).
The Annual Report 2024 will be available from 28 March 2025 at www.mediclin.de in German and English. You are welcome to subscribe to the IR newsletter here to receive regular updates on all topics relevant to investors. MEDICLIN Aktiengesellschaft Okenstraße 27 77652 Offenburg Germany Investor Relations Ender Gülcan Phone +49 781/488-326 ender.guelcan@mediclin.de www.mediclin.de About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 31 clinics, six care facilities and ten medical care centers. The Group has around 8,200 beds/care places and employs around 9,900 people. In a strong network, MEDICLIN offers the patients integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs. MEDICLIN ─ a company of the Asklepios Group
27.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | MEDICLIN AG |
| Okenstraße 27 | |
| 77652 Offenburg | |
| Germany | |
| Phone: | +49 (0)781 488-326 |
| Fax: | +49 (0)781 488-184 |
| E-mail: | ender.guelcan@mediclin.de |
| Internet: | www.mediclin.de |
| ISIN: | DE0006595101 |
| WKN: | 659510 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2092787 |
| End of News | EQS News Service |
|
|
2092787 27.02.2025 CET/CEST
Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL.
| Die wichtigsten Finanzdaten auf einen Blick | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Umsatzerlöse1 | 673,09 | 659,86 | 673,14 | 704,70 | 730,07 | 748,75 | 778,00 | |
| EBITDA1,2 | 93,58 | 77,50 | 85,22 | 90,92 | 98,73 | 103,77 | 115,00 | |
| EBITDA-Marge3 | 13,90 | 11,75 | 12,66 | 12,90 | 13,52 | 13,86 | 14,78 | |
| EBIT1,4 | 22,41 | 0,15 | 11,56 | 19,52 | 12,72 | 53,49 | 63,00 | |
| EBIT-Marge5 | 3,33 | 0,02 | 1,72 | 2,77 | 1,74 | 7,14 | 8,10 | |
| Jahresüberschuss1 | 9,68 | -0,04 | 1,49 | 9,72 | -10,72 | 24,91 | 35,00 | |
| Netto-Marge6 | 1,44 | -0,01 | 0,22 | 1,38 | -1,47 | 3,33 | 4,50 | |
| Cashflow1,7 | 69,59 | 118,69 | 81,97 | 34,64 | 78,00 | 50,57 | 74,00 | |
| Ergebnis je Aktie8 | 0,20 | -0,19 | 0,03 | 0,20 | -0,23 | 0,52 | 0,74 | |
| Dividende8 | 0,05 | 0,00 | 0,00 | 0,00 | 0,00 | 0,04 | 0,04 | |
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: KPMG
Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.
| INVESTOR-INFORMATIONEN | ||||||
| ©boersengefluester.de | ||||||
| Mediclin | ||||||
| WKN | ISIN | Rechtsform | Börsenwert | IPO | Einschätzung | Plus Code |
| 659510 | DE0006595101 | AG | 178,60 Mio € | 06.12.2000 | Kaufen | 8FW9FWGV+63 |
| KGV 2026e | KGV 10Y-Ø | BGFL-Ratio | Shiller-KGV | KBV | KCV | KUV |
| 5,78 | 17,70 | 0,33 | 17,01 | 0,73 | 2,22 | 0,24 |
|
Dividende '2023 in € |
Dividende '2024 in € |
Dividende '2025e in € |
Div.-Rendite '2025e in % |
| 0,00 | 0,04 | 0,04 | 1,06% |
| Hauptversammlung | Q1-Zahlen | Q2-Zahlen | Q3-Zahlen | Bilanz-PK |
| 28.06.2026 | 04.05.2026 | 30.07.2026 | 04.11.2025 | 27.03.2026 |
| Abstand 60-Tage-Linie | Abstand 200-Tage-Linie | Performance YtD | Kursveränderung 52 Wochen | IPO |
| +9,53% | +21,10% | +55,37% | +56,67% | -65,82% |
Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.